These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 14505916)
41. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine. Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648 [TBL] [Abstract][Full Text] [Related]
42. Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in Italy. Zanetti A; Desole MG; Romanò L; d'Alessandro A; Conversano M; Ferrera G; Panico MG; Tomasi A; Zoppi G; Zuliani M; Thomas S; Soubeyrand B; Eymin C; Lockhart S Vaccine; 2017 Jul; 35(32):4034-4040. PubMed ID: 28624307 [TBL] [Abstract][Full Text] [Related]
43. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. el-Reshaid K; al-Mufti S; Johny KV; Sugathan TN Vaccine; 1994; 12(3):223-34. PubMed ID: 8165854 [TBL] [Abstract][Full Text] [Related]
44. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity. Khouri JM; Motter RN; Arnon SS Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762 [TBL] [Abstract][Full Text] [Related]
45. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642 [TBL] [Abstract][Full Text] [Related]
46. Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children. Gatchalian SR; Ramakrishnan G; Bock HL; Lefevre I; Jacquet JM Hum Vaccin; 2010 Aug; 6(8):664-72. PubMed ID: 20657177 [TBL] [Abstract][Full Text] [Related]
47. Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome-DNA complexes as adjuvant. Cote PJ; Butler SD; George AL; Fairman J; Gerin JL; Tennant BC; Menne S J Med Virol; 2009 Oct; 81(10):1760-72. PubMed ID: 19697409 [TBL] [Abstract][Full Text] [Related]
48. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. Gatchalian S; Reyes M; Bernal N; Lefevre I; David MP; Han HH; Bock HL; Wolter J; Schuerman L Hum Vaccin; 2005; 1(5):198-203. PubMed ID: 17012860 [TBL] [Abstract][Full Text] [Related]
49. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants. Deichmann KA; Ferrera G; Tran C; Thomas S; Eymin C; Baudin M Vaccine; 2015 May; 33(20):2379-86. PubMed ID: 25765966 [TBL] [Abstract][Full Text] [Related]
50. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Alberer M; Gnad-Vogt U; Hong HS; Mehr KT; Backert L; Finak G; Gottardo R; Bica MA; Garofano A; Koch SD; Fotin-Mleczek M; Hoerr I; Clemens R; von Sonnenburg F Lancet; 2017 Sep; 390(10101):1511-1520. PubMed ID: 28754494 [TBL] [Abstract][Full Text] [Related]
51. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252 [TBL] [Abstract][Full Text] [Related]
52. Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine. Beck BR; Hatz CF; Loutan L; Steffen R J Travel Med; 2004; 11(4):201-6. PubMed ID: 15541221 [TBL] [Abstract][Full Text] [Related]
53. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine. Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596 [TBL] [Abstract][Full Text] [Related]
54. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults. Raz R; Koren R; Bass D Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195 [TBL] [Abstract][Full Text] [Related]
55. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa. Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322 [TBL] [Abstract][Full Text] [Related]
56. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Halperin SA; Dobson S; McNeil S; Langley JM; Smith B; McCall-Sani R; Levitt D; Nest GV; Gennevois D; Eiden JJ Vaccine; 2006 Jan; 24(1):20-6. PubMed ID: 16198027 [TBL] [Abstract][Full Text] [Related]
57. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Krawczyk A; Ludwig C; Jochum C; Fiedler M; Heinemann FM; Shouval D; Roggendorf M; Roggendorf H; Lindemann M Vaccine; 2014 Sep; 32(39):5077-82. PubMed ID: 24975813 [TBL] [Abstract][Full Text] [Related]
58. [Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice]. Chen H; Deng Y; Tan W; Wang W; Yin X; Guan J; Wang W; Ruan L Sheng Wu Gong Cheng Xue Bao; 2010 Jan; 26(1):74-8. PubMed ID: 20353095 [TBL] [Abstract][Full Text] [Related]
59. Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China. Wang ZZ; Gao YH; Lu W; Jin CD; Zeng Y; Yan L; Ding F; Li T; Liu XE; Zhuang H Hum Vaccin Immunother; 2017 Apr; 13(4):909-915. PubMed ID: 27874311 [TBL] [Abstract][Full Text] [Related]
60. Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice. Mahboubi A; Fazeli MR; Dinarvand R; Samadi N; Sharifzadeh M; Ilka H; Azadi S; Soleimanian R; Kalkouei H; Hajikhanmirzaei R; Valadkhani M Iran J Immunol; 2008 Sep; 5(3):163-70. PubMed ID: 18791283 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]